The latest trend in health and fitness tracking may sound familiar: wearing continuous glucose monitors (CGMs). Many people ...

Of the hundreds of millions of people living with diabetes, most liv. Dexcom wants to make sure they have tools to manage it.

Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient ...

As the U.S. stock market navigates a period of mixed performance, with major indices like the Dow Jones and S&P 500 experiencing fluctuations amid economic uncertainties and tariff concerns, investors ...

Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $98.00. The ...

A survey conducted by the continuous glucose monitor maker Dexcom found that just over half of healthcare providers ranked technology and education as having larger impacts when it comes | Dexcom ...

Both stocks should deliver excellent returns to investors patient enough to hold through volatility. Equity markets started ...

Dexcom (Nadsaq:DXCM) announced today that it launched a new multi-region report evaluating type 2 diabetes treatments.

The Diabetic Care Devices Market is projected to grow from $16.6 billion in 2024 to $26.8 billion by 2029, at a CAGR of 10.1%. This report provides a comprehensive analysis of diabetes monitoring ...

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system,1 ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...